

**UNITED STATES DEPARTMENT OF COMMERCE****United States Patent and Trad mark Offic**Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

B

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/103,745 06/24/98 AGRAWAL

S 475.08.642CI

HM12/0502

EXAMINER

WAYNE A KEOWN
HALE AND DORR
60 STATE STREET
BOSTON MA 02109

WANG, A

ART UNIT	PAPER NUMBER
----------	--------------

1635

B

DATE MAILED:

05/02/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary	Application No.	Applicant(s)
	09/103,745	AGRAWAL, SUDHIR
Examiner	Art Unit	
Andrew Wang	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on ____.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-4 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) Claim(s) ____ is/are allowed.
- 6) Claim(s) 1-4 is/are rejected.
- 7) Claim(s) ____ is/are objected to.
- 8) Claims ____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on ____ is/are objected to by the Examiner.
- 11) The proposed drawing correction filed on ____ is: a) approved b) disapproved.
- 12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. ____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- 15) Notice of References Cited (PTO-892)
- 16) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 18) Interview Summary (PTO-413) Paper No(s) ____.
- 19) Notice of Informal Patent Application (PTO-152)
- 20) Other: _____

Application/Control Number: 09/103,745

Page 2

Art Unit: 1635

DETAILED ACTION

1. The request filed on 6 December 2000 for a Continued Prosecution Application (CPA) under 37 CFR 1.53(d) based on parent Application No. 09/103,745 is acceptable and a CPA has been established. An action on the CPA follows.

2. Claims 1-3 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-7 of U.S. Patent No. 5,856,462 for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

3. Claims 1-4 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

4. Claim 1 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the reduced side effects for the CpG oligos having the modifications listed in claim 1 and/or shown in Example 2, does not reasonably provide enablement for CpG oligos

Art Unit: 1635

having simply phosphorothioate linkages as in claim 1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

5. Claims 3 and 4 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for methods in cells in culture and for reduced side effects for the CpG oligos having the modifications listed in claim 2 and/or shown in Example 2, does not reasonably provide enablement for methods in whole organisms and for CpG oligos having simply phosphorothioate linkages as in claim 1. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

6. Claims 1 and 2 are rejected under 35 U.S.C. 102(a) as being clearly anticipated by Krieg et al. (WO 96/02555 or Antisense or Nucleic Acid Drug Devel.) for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

Art Unit: 1635

7. Claim 1 is rejected under 35 U.S.C. 102(b) as being clearly anticipated by Krieg et al. (Nature) for the same reasons of record as set forth in the Office action mailed September 9, 1999.

Applicants have not provided any arguments addressing the rejection of record.

8. All claims are drawn to the same invention claimed in the parent application prior to the filing of this Continued Prosecution Application under 37 CFR 1.53(d) and could have been finally rejected on the grounds and art of record in the next Office action. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing under 37 CFR 1.53(d). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


Art Unit: 1635

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Andrew Wang whose telephone number is (703) 306-3217. The examiner can normally be reached on Monday to Thursday from 7:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader, can be reached on (703) 308-0447. The fax phone number for this Group is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Andrew Wang
May 2, 2001



Andrew Wang
Primary Examiner
Technology Center 1600

ANDREW WANG
PATENT EXAMINER